Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Takeda
City of Hope Medical Center
NextCure, Inc.
Brown University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Celgene
City of Hope Medical Center
City of Hope Medical Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline
Ono Pharmaceutical Co., Ltd.
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Nebraska
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Virginia Commonwealth University
Medical College of Wisconsin
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Takeda
M.D. Anderson Cancer Center
Pfizer
M.D. Anderson Cancer Center
Incyte Corporation
Takeda
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Novartis
Roswell Park Cancer Institute
Novartis